• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Jan 4;38(1):110184.
doi: 10.1016/j.celrep.2021.110184.
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections


Paola Brandi[SUP] 1 [/SUP], Laura Conejero[SUP] 1 [/SUP], Francisco J Cueto[SUP] 1 [/SUP], Sarai Martínez-Cano[SUP] 2 [/SUP], Gillian Dunphy[SUP] 1 [/SUP], Manuel J Gómez[SUP] 1 [/SUP], Carlos Relaño[SUP] 1 [/SUP], Paula Saz-Leal[SUP] 1 [/SUP], Michel Enamorado[SUP] 1 [/SUP], Ana Quintas[SUP] 1 [/SUP], Ana Dopazo[SUP] 1 [/SUP], Joaquín Amores-Iniesta[SUP] 1 [/SUP], Carlos Del Fresno[SUP] 3 [/SUP], Estanislao Nistal-Villán[SUP] 4 [/SUP], Carlos Ardavín[SUP] 5 [/SUP], Antonio Nieto[SUP] 6 [/SUP], Miguel Casanovas[SUP] 7 [/SUP], José Luis Subiza[SUP] 7 [/SUP], David Sancho[SUP] 8 [/SUP]



Affiliations

Abstract

MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity.

Keywords: Candida albicans; human monocytes; influenza; macrophages; mucosal; polybacterial immunomodulator; respiratory infection; trained immunity; vaccine; viral infection.
 
Back
Top Bottom